Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS

Project description

Rebooting the brain’s cleanup crew

In the fight against Alzheimer’s and the rare, devastating Nasu-Hakola disease, scientists have identified a common culprit: a glitch in the TREM2 gene. This mutation effectively ‘breaks’ microglia (the brain’s waste-clearance cells), leaving them unable to scrub away the toxic plaques and inflammation that drive cognitive decline. The EIC-funded TREM2MEDS project aims to explore a radical solution. It is engineering blood-forming stem cells to carry a functional TREM2 gene. Researchers are creating an ‘internal repair crew’ that can migrate into the central nervous system. In early trials, these cells dismantled amyloid-beta buildup and calmed brain inflammation. The project aims to turn this biological bypass into a therapy, offering a way to reboot the brain’s own defence systems.

Objective

TREM2MEDS emerges from the ERC PoC 2022 project TREM2μENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimer’s Disease (AD) and Nasu-Hakola Disease (NHD) in murine models. A relevant proportion of AD cases and all forms of NHD are caused by pathogenic mutations in the TREM2 gene, which lead to microglia dysfunction contributing to and/or causing the onset and manifestations of AD and NHD. TREM2MEDS approach involves the transplantation of hematopoietic stem/progenitor cells (HSPCs) engineered by lentiviral vectors (LVs) to express robust levels of the Triggering receptor expressed on myeloid cells 2 (TREM2) in their central nervous system (CNS) myeloid/microglial progeny. The engineered cells have shown the ability to reduce and prevent Aβ accumulation, mitigate neuroinflammation and restore physiological scavenging functions in the diseased CNS, benefiting AD and NHD in robust animal models. In TREM2MEDS, we will exploit these findings for transition of the approach from TRL 4 to TRL 5/6 by generating IMPD-enabling data and packages that will allow launching, at project completion, a first-in-human Phase I clinical trial of TREM2-HSPC gene therapy in AD & NHD patients carrying TREM2 hypofunctional variants. The restoration of TREM2 function in microglia, by intervening on key mechanisms contributing to neurodegeneration, has the potential to overcome the limited efficacy of current treatments for AD, which only exert symptomatic but not curative effects. Through this work we will thus bring to clinical testing an approach intended to become the benchmark in the treatment of AD and NHD, and possibly other dementias.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2023-TRANSITION-01

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI PADOVA
Net EU contribution
€ 1 623 131,25
Address
VIA 8 FEBBRAIO 2
35122 Padova
Italy
Region
Nord-Est Veneto Padova
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 732 131,25

Participants (3)